BBC NEWSAmericasAfricaEuropeMiddle EastSouth AsiaAsia Pacific
BBCiNEWS  SPORT  WEATHER  WORLD SERVICE  A-Z INDEX    

BBC News World Edition
 You are in: Health 
News Front Page
Africa
Americas
Asia-Pacific
Europe
Middle East
South Asia
UK
Business
Entertainment
Science/Nature
Technology
Health
Medical notes
-------------
Talking Point
-------------
Country Profiles
In Depth
-------------
Programmes
-------------
BBC Sport
News image
BBC Weather
News image
SERVICES
-------------
EDITIONS
Thursday, 14 November, 2002, 17:02 GMT
Mumps vaccine warning challenged
MMR jab
Many parents are looking for alternatives to MMR
A warning from UK officials not to use a brand of single mumps vaccine imported from Eastern Europe has been attacked by private clinics.

The government's Committee on the Safety of Medicines (CSM) says that the Pavivac vaccine - made in the Czech Republic - should not be used by doctors until futher checks have been completed.

It says that the safety of the vaccine cannot be confirmed until more information about its manufacture and storage is put before it.


We are shocked that the Medicines Control Agency could be so cavalier in its approach to vaccine approval

Sarah Dean, Direct Health 2000
However, it has been accused of "appalling scaremongering" by a leading single jab supplier.

Only a small number of single mumps vaccines used in the UK come from the Czech source.

Out of 30,000 single mumps jabs imported this year, 5,720 were Pavivac.

Many parents have turned to single versions of measles, mumps and rubella vaccinations due to concerns about the safety of the combined MMR jab.

Clinics which have imported these jabs in the past are to be contacted and told not to use remaining stocks or import more.

The Medicines Control Agency (MCA) - whose job it is to check on the quality of medicines used in the UK - has been told to oppose all future imports of the Pavivac vaccine until evidence of its safety can be provided.

'Precautionary'

CSM chairman Professor Alastair Breckenridge said: "There are a number of major questions about the manufacture, testing and storage of the unlicensed vaccine Pavivac which are not answered by the information currently available.


There are a number of major questions about the manufacture, testing and storage of the unlicensed vaccine Pavivac which are not answered

Professor Alaistair Breckenridge, CSM
"Because of this lack of information, we are advising that its importation and use should be halted as a precautionary measure.

"Further information and clarification has been urgently requested."

However, Sarah Dean, the managing director of Direct Health 2000, which provides single jabs through a network of clinics, attacked the move.

She said she believed it was an attempt by the Department of Health to restrict the choice of single vaccines available to parents.

She said: "We believe the Medicines Control Agency is guilty of both a lapse of duty and appalling scaremongering in its handling of use of the Pavivac mumps vaccine in the UK.

"Our importer was told by the MCA that it was free to supply Pavivac on May 14, 2002.

"Yet six months later the vaccine is suspended because of unidentified 'concerns'.

"We are shocked that the MCA could be so cavalier in its approach to vaccine approval."

Doctors in the UK are theoretically allowed to use any drug on any patient, even if it is not licensed for that purpose - or at all.

Several of the types of single vaccine used in place of MMR are unlicensed.

 WATCH/LISTEN
 ON THIS STORY
The BBC's Karen Allen
"The vaccine is simply an unknown quantity"
See also:

06 Nov 02 | Health
07 Nov 02 | Health
08 Oct 02 | England
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Health stories are at the foot of the page.


E-mail this story to a friend

Links to more Health stories

© BBC^^ Back to top

News Front Page | Africa | Americas | Asia-Pacific | Europe | Middle East |
South Asia | UK | Business | Entertainment | Science/Nature |
Technology | Health | Talking Point | Country Profiles | In Depth |
Programmes